SNDX

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 36.00 USD with a low forecast of 22.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Syndax Pharmaceuticals Inc revenue for the last quarter amounts to 45.87M USD, increased 266.97 % YoY.

Syndax Pharmaceuticals Inc. EPS for the last quarter amounts to -0.70 USD, decreased -28.57 % YoY.

Syndax Pharmaceuticals Inc (SNDX) has 270 emplpoyees as of December 15 2025.

Today SNDX has the market capitalization of 1.77B USD.